吡咯替尼联合维生素B_(6)对HER-2阳性乳腺癌患者疗效及手足综合征的影响

The effect of pyrrotinib combined with vitamin B_(6) on the curative effect of HER-2 positive breast cancer patients and hand-foot syndrome

目的探讨吡咯替尼联合维生素B_(6)对HER-2阳性乳腺癌患者疗效及手足综合征的影响。方法选取2018年5月~2021年4月收治的HER-2阳性乳腺癌患者,随机将其分为观察组(n=35)和对照组(n=35)。对照组采用常规化疗,观察组采用吡咯替尼联合维生素B_(6)进行治疗,观察两组患者3个月后的治疗效果和血清肿瘤标志物[血清癌胚抗原(CEA)、糖类抗原(CA153)、组织多肽特异抗原(TPS)]指标以及手足综合征发生率。结果观察组的客观缓解率和疾病控制率明显高于对照组(P<0.05)。治疗前两组患者血清癌胚抗原、糖类抗原以及组织多肽特异抗原水平对比无明显差异(P>0.05),治疗后观察组患者的血清癌胚抗原、糖类抗原以及组织多肽特异抗原水平明显低于对照组(P<0.05)。治疗后观察组的手足综合征发生率明显低于对照组(P<0.05)。结论吡咯替尼联合维生素B_(6)能够提高对HER-2阳性乳腺癌患者的治疗效果,降低HER-2阳性乳腺癌患者的血清癌胚抗原、糖类抗原以及组织多肽特异抗原水平,还可以减少HER-2阳性乳腺癌患者手足综合征的发病率。

Objective To investigate the effect of pyrrotinib combined with vitamin B_(6) on the curative effect of HER-2 positive breast cancer patients and hand-foot syndrome.Methods The patients with HER-2 positive breast cancer admitted in our hospital from May 2018 to April 2021 were selected and randomly divided into the observation group(n=35)and the control group(n=35).The control group was treated with conventional chemotherapy,and the observation group was treated with pyrrotinib combined with vitamin B_(6) in the control group.The treatment effect and serum tumor markers[serum carcinoembryonic antigen(CEA),carbohydrate antigen(CA153),tissue polypeptide specific antigen(TPS)]indicators.Results The objective remission rate and disease control rate of the observation group were significantly higher than those of the control group(P<0.05).Before treatment,there was no significant difference in serum carcinoembryonic antigen,carbohydrate antigen and tissue polypeptide specific antigen indexes between the two groups of patients(P>0.05).After treatment,the serum carcinoembryonic antigen,carbohydrate antigen and tissue polypeptide specific antigen indexes of the observation group were obvious lower than the control group(P<0.05).After treatment,the incidence of hand-foot syndrome in the observation group was significantly lower than that in the control group(P<0.05).Conclusion Pirrotinib combined with vitamin B_(6) can improve the therapeutic effect of patients with HER-2 positive breast cancer,reduce serum carcinoembryonic antigen,carbohydrate antigen and tissue polypeptide specific antigen indexes of HER-2 positive breast cancer patients,and can also reduce the incidence of hand-foot syndrome in patients with HER-2 positive breast cancer.